METHODS OF TREATING METABOLIC DISEASE

It has been discovered that SIRT6 functions as a histone H3K9 deacetylase to control the expression of multiple glycolytic genes. Specifically, SIRT6 appears to function as a co-repressor of the transcription factor Hif1?, a critical regulator of nutrient stress responses. This invention relates gen...

Full description

Saved in:
Bibliographic Details
Main Author MOSTOSLAVSKY, RAUL
Format Patent
LanguageEnglish
French
Published 31.03.2011
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:It has been discovered that SIRT6 functions as a histone H3K9 deacetylase to control the expression of multiple glycolytic genes. Specifically, SIRT6 appears to function as a co-repressor of the transcription factor Hif1?, a critical regulator of nutrient stress responses. This invention relates generally to methods of reducing expression or activity of SIRT6 to reduce or inhibit hyperglycemia or obesity in a subject. On a découvert que SIRT6 fonctionne comme une histone H3K9 désacétylase pour réguler l'expression de multiples gènes glycolytiques. Plus spécifiquement, SIRT6 semble opérer comme un co-répresseur du facteur de transcription Hif1, un régulateur critique des réponses au stress nutritif. De manière générale, cette invention concerne des procédés de réduction de l'expression ou de l'activité de SIRT6 pour réduire ou inhiber l'hyperglycémie ou l'obésité chez un sujet.
Bibliography:Application Number: WO2010US49986